Status:
COMPLETED
Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension
Lead Sponsor:
Mansoura University
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The 6th World Symposium on Pulmonary Hypertension, pre-capillary pulmonary hypertension (PH) has been defined as mean pulmonary arterial pressure (mPAP) \>20 mm Hg with a pulmonary arterial wedge pres...
Detailed Description
Right Heart Catheterization (RHC) is the diagnostic gold standard for pulmonary hypertension (PH), In fact, RHC is the definitive diagnostic technique for reliably confirming whether a patient has PAH...
Eligibility Criteria
Inclusion
- All adult patients with clinical and echocardiographic features suggestive of pulmonary hypertension after exclusion of all secondary causes.
Exclusion
- groups 2,3,4,5 Pulmonary hypertension
- Hemodynamic instability.
- Absolute contraindications to pulmonary artery catheter (PAC) placement include: Infection at the insertion site The presence of a right ventricular assist device Insertion during cardiopulmonary bypass Lack of consent
- Relative contraindications to the placement of a PAC include a coagulopathy (international normalized ratio \>1.5), thrombocytopenia (platelet count \<50,000/microL), electrolyte disturbances (hypo- or hyper-kalemia, -magnesemia, -natremia, -calcemia), and severe acid-base disturbances (eg, pH \<7.2 or \>7.5).
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07214129
Start Date
March 1 2022
End Date
March 1 2024
Last Update
October 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohamed AbdElmoniem
Al Mansurah, Egypt, 35516